A team of leading infectious disease scientists from academia and industry have been awarded £17.9 million to identify new ...

The booth of GSK. [Photo/IC] People living with HIV and people with potential exposure to HIV in China are expected to leverage more of GlaxoSmithKline's innovative research results for the prevention ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

Aurobindo Pharma, Cipla, and Viatris to supply long-acting injectable cabotegravir for HIV treatment in 133 countries.

UK-based ViiV Healthcare, the HIV specialist company majority owned by GSK, with Pfizer and Shionogi as shareholders, has announced data from the Phase IIIb VOLITION study.

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Hyderabad-based drugmaker Aurobindo Pharma will produce and supply Cabotegravir, a long-acting injectable HIV treatment, ...

Aurobindo Pharma will manufacture and supply these injectable HIV treatment across 133 countries, including several low and ...

ViiV & MPP extend voluntary licensing long-acting injectable HIV treatment, Indian pharma to benefit: Our Bureau, Bengaluru Tuesday, July 15, 2025, 12:45 Hrs [IST] ViiV Healthcare ...